RBCx features AmacaThera’s journey
RBCx, the tech banking and investment arm of the Royal Bank of Canada, has featured AmacaThera’s drug development platform and start-up journey.
Read more
Shoichet Will Help Accelerate Scientific Innovation and Advance Science in Government Decision-Making.
Ontario has appointed Molly Shoichet to advance science and innovation in the province — and to make government smarter and more effective by providing decision-makers with the world’s best scientific research and evidence.
The Chief Scientist will advise Premier Kathleen Wynne directly on key scientific matters, demonstrating Ontario’s ongoing commitment to grow our economy by investing in scientific research and promoting our world-class science both at home and to international audiences. Shoichet, a professor at the University of Toronto and a member of the Order of Ontario, will report to Reza Moridi, Minister of Research, Innovation and Science.
An internationally respected and award-winning expert in the study of polymers for drug delivery and tissue regeneration, as a teacher, mentor and researcher Shoichet has demonstrated her dedication to the advancement of scientific knowledge and excellence.
In the coming months, Shoichet will help develop Ontario’s strategic research agenda and grow the province’s reputation as a top destination for global research talent. The Chief Scientist will also provide advice informed by science to help government decision-makers tackle some of the greatest challenges of our time, such as climate change, aging populations and the impact of transformative technologies.
Supporting research and innovation is part of Ontario’s plan to create fairness and opportunity during this period of rapid economic change. The plan includes a higher minimum wage and better working conditions, free tuition for hundreds of thousands of students, easier access to affordable child care, and free prescription drugs for everyone under 25 through the biggest expansion of medicare in a generation.
Quick Facts
Quotes
“Scientists right here in Ontario are doing amazing research that is fundamental to our progress and prosperity. As we tackle some of today’s biggest challenges, science plays an increasingly vital role in helping governments make informed decisions. I am excited that Molly Shoichet will become Ontario’s first Chief Scientist. I look forward to her thought leadership and advice on how we can strengthen the research and innovation happening across our province — and how we can apply scientific evidence to make government smarter and more effective.”
- Kathleen Wynne
Premier of Ontario
“I congratulate Molly Shoichet for becoming Ontario’s first Chief Scientist. She is one of the top biomedical scientists in the country, with in-depth knowledge of Ontario’s research community. As Chief Scientist, she will help us continue a proud tradition of science and research excellence through evidence-based decision making and will open the world to the incredible innovative talent and technologies Ontario has to offer.”
- Reza Moridi
Minister of Research, Innovation and Science
“We are pleased to see the Government of Ontario moving forward on the appointment of a Chief Scientist. We now face a world that is changing more rapidly than at any other time in history, and governments need to understand emerging science in order to craft policy informed by the best scientific advice.”
- Alan Bernstein
President of the Canadian Institute for Advanced Research (CIFAR)
RBCx, the tech banking and investment arm of the Royal Bank of Canada, has featured AmacaThera’s drug development platform and start-up journey.
Read more
AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company's lead asset in non-opioid acute pain management. Read more
AmacaThera, a leader in the development of novel injectable, localized therapeutics based upon its AmacaGel delivery platform, announced the closing of a CAD$4.0 million financing round.Read more